Tirzepatide and semaglutide are the two most consequential weight-loss drugs in medicine today. Both are injectable GLP-1 receptor agonists. Both produce substantial weight loss that no previous medication could match. Both are available through telehealth.
But they are not equivalent. The mechanism is different, the clinical trial data is different, and the practical access picture differs in ways that matter to patients making a real decision. This guide covers what the evidence actually shows — molecule to molecule.
The Core Difference: One Receptor vs. Two
The mechanism explains most of the efficacy gap.
Semaglutide (the active ingredient in Ozempic, Wegovy, and Rybelsus) is a GLP-1 receptor agonist. It mimics the GLP-1 hormone your gut naturally releases after eating. GLP-1 receptor activation:
- Stimulates insulin secretion in response to elevated blood glucose
- Suppresses glucagon (which would otherwise raise blood sugar)
- Slows gastric emptying, extending satiety after meals
- Acts on hypothalamic receptors to suppress appetite and reduce food intake
Tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 receptor agonist. It activates GLP-1 receptors exactly as semaglutide does — and also activates GIP (glucose-dependent insulinotropic polypeptide) receptors. The GIP component:
- Enhances insulin secretion synergistically with GLP-1
- Appears to improve insulin sensitivity in fat cells
- May reduce fat storage efficiency and shift energy utilization
- Potentially reduces the nausea associated with high-dose GLP-1 activation
The dual-receptor mechanism is why tirzepatide consistently outperforms semaglutide in clinical trials. It is not simply a stronger GLP-1 agonist — it targets a different biological pathway simultaneously.
What the Clinical Trials Show
STEP Trials (Semaglutide)
The STEP program (Semaglutide Treatment Effect in People with Obesity) established semaglutide's weight-loss profile in a series of pivotal trials. The key numbers:
STEP 1 (68 weeks, adults with obesity, no diabetes): Mean weight loss of 14.9% of body weight at semaglutide 2.4mg/week. 86% of patients achieved ≥5% weight loss; 32% achieved ≥20%.
STEP 2 (68 weeks, adults with type 2 diabetes): Mean weight loss of 9.6% — lower than the non-diabetic cohort, consistent with the known blunting effect of type 2 diabetes on GLP-1 response.
STEP 4 (Maintenance): Patients who continued semaglutide maintained weight loss; those who switched to placebo regained approximately two-thirds of lost weight by week 68, confirming the ongoing medication requirement.
SURMOUNT Trials (Tirzepatide)
The SURMOUNT program established tirzepatide's weight-loss profile, with consistently larger numbers than STEP.
SURMOUNT-1 (72 weeks, adults with obesity, no diabetes): Mean weight loss of 15.0% at 5mg, 19.5% at 10mg, and 20.9% at 15mg. At the highest dose, 36% of patients achieved ≥25% weight loss — a milestone that semaglutide did not reach in its trials.
SURMOUNT-2 (72 weeks, adults with type 2 diabetes): Mean weight loss of 13.4% at 15mg — notably higher than STEP 2's 9.6% for semaglutide in the same diabetic population.
SURMOUNT-5: The Head-to-Head
The most important data point came from SURMOUNT-5, the first randomized controlled trial directly comparing tirzepatide to semaglutide in adults with obesity. Results over 72 weeks:
| Drug | Mean Weight Loss | ≥20% Weight Loss | ≥25% Weight Loss |
|---|---|---|---|
| Tirzepatide 10–15mg | 20.2% | 44% | 25% |
| Semaglutide 2.4mg (Wegovy) | 13.7% | 20% | 10% |
Tirzepatide produced approximately 47% more weight loss than semaglutide in this head-to-head comparison. This was statistically significant and clinically meaningful.
Important caveat: SURMOUNT-5 compared tirzepatide at its higher doses (10mg and 15mg) to semaglutide at its maximum approved dose (2.4mg). Both drugs were used at their respective ceilings. The difference is real — but it reflects the best each drug can do, not a comparison at equivalent biological activity.
Head-to-Head Comparison Table
| Tirzepatide | Semaglutide | |
|---|---|---|
| Brand names | Mounjaro (diabetes), Zepbound (weight) | Ozempic (diabetes), Wegovy (weight) |
| Mechanism | Dual GIP + GLP-1 agonist | GLP-1 agonist |
| Avg. weight loss (obesity trials) | 15–21% (dose-dependent) | ~15% |
| Head-to-head result | 20.2% (SURMOUNT-5) | 13.7% (SURMOUNT-5) |
| Max weekly dose | 15mg | 2.4mg (Wegovy) / 2.0mg (Ozempic) |
| Titration schedule | 4 weeks per dose step | 4 weeks per dose step |
| Brand list price | ~$1,000–$1,100/mo | ~$1,300–$1,400/mo (Wegovy) |
| Compounded availability | Available, fewer providers | Widely available |
| Compounded price range | $150–$450/mo | $99–$450/mo |
| Insurance coverage (weight) | Rarely covered | Rarely covered |
| FDA-approved for obesity | Yes (Zepbound, 2023) | Yes (Wegovy, 2021) |
| Cardiovascular outcomes data | Limited (trial ongoing) | Yes (SELECT trial, 2023) |
Side Effects: How Do They Compare?
Both drugs share the same core GLP-1-driven side effect profile. The most commonly reported adverse events in clinical trials:
Gastrointestinal (both drugs):
- Nausea: 20–44% of patients
- Diarrhea: 13–30%
- Vomiting: 5–24%
- Constipation: 10–24%
Side effects are worst during dose escalation — the weeks immediately after a dose increase — and typically improve as the body adapts to each new dose level. Most patients who stay on the medication report substantially reduced GI symptoms by month 3–4.
Is one drug harder to tolerate? Clinical trial data does not show a clear winner on tolerability. Some analyses suggest tirzepatide's GIP component may slightly reduce nausea compared to a pure GLP-1 agonist — GIP activation appears to counteract some of the nausea signaling that GLP-1 produces. In practice, individual responses vary significantly.
Serious adverse events (both drugs):
- Thyroid C-cell tumor warning (class-level; based on rodent data — clinical relevance in humans is uncertain)
- Pancreatitis risk (rare)
- Gallbladder disease — particularly gallstones, more common with rapid weight loss
- Hypoglycemia risk in patients also taking insulin or sulfonylureas
Both drugs carry identical contraindications: personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN 2).
Cost and Access
Brand-Name Pricing (Without Insurance)
Without insurance, both drugs are expensive. List prices as of 2026:
- Zepbound (tirzepatide for weight): approximately $1,000–$1,100/month
- Wegovy (semaglutide for weight): approximately $1,300–$1,400/month
Manufacturer savings cards can reduce out-of-pocket costs significantly for commercially insured patients — but savings programs vary, have eligibility requirements, and change periodically. Check manufacturer websites directly for current terms.
Compounded Access Through Telehealth
Compounded versions of both molecules are available through GLP-1 telehealth platforms at substantially lower prices:
- Compounded semaglutide: widely available, $99–$450/month depending on dose and provider
- Compounded tirzepatide: available through fewer platforms, $150–$450/month
The regulatory landscape for compounded GLP-1 medications has evolved. Consult your provider or a telehealth platform for current availability in your state.
Insurance Coverage
Commercial health insurance rarely covers either drug for weight loss alone. Coverage is more common when a type 2 diabetes diagnosis is present (Mounjaro and Ozempic have diabetes indications; Zepbound and Wegovy do not). Medicaid coverage varies significantly by state.
Which Drug Is Right for You?
Neither drug is universally right for every patient. The decision depends on:
Choose tirzepatide if:
- Maximum weight loss is the priority and you've discussed the SURMOUNT data with your provider
- You've had a partial response to semaglutide and want to try escalating to a dual-agonist mechanism
- Cost differences are not prohibitive or compounded tirzepatide is accessible in your area
Consider semaglutide if:
- You need the most established safety data (Ozempic has been in use since 2017; Wegovy since 2021)
- Cardiovascular risk reduction is a priority — semaglutide has a broader cardiovascular evidence base (SELECT trial showed 20% reduction in MACE in high-risk patients)
- Cost is a primary concern — compounded semaglutide is more widely available at lower prices
- Tirzepatide isn't accessible in your state or through your preferred provider
The honest reality: Most patients who start on semaglutide because of access or cost are making a reasonable, evidence-based choice. Semaglutide produces meaningful weight loss — often 10–15% of body weight — that would have been considered extraordinary by prior pharmacological standards. Tirzepatide produces more weight loss on average, but "more" doesn't mean semaglutide "doesn't work."
The best drug is the one you can access, afford, and stay on long-term.
Finding the Right Provider
The drug choice is only part of the equation. Protocol quality — titration schedule, prescriber responsiveness, monitoring — matters significantly for outcomes and safety. A well-run semaglutide program outperforms a poorly run tirzepatide program.
Ready to find a GLP-1 provider that offers the medication you need? Take our provider quiz to see options matched to your location, medication preference, and budget.
Clinical data sourced from STEP 1 (NEJM 2021), SURMOUNT-1 (NEJM 2022), SURMOUNT-5 (NEJM 2024), and SELECT trial (NEJM 2023). This article is for informational purposes and does not constitute medical advice. Discuss medication choices with a licensed healthcare provider.